Hostname: page-component-6bf8c574d5-8gtf8 Total loading time: 0 Render date: 2025-02-24T08:22:03.912Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Dopaminomimetic Psychosis in Parkinson's Disease with Electroconvulsive Therapy

Published online by Cambridge University Press:  18 September 2015

T.A. Hurwitz ,
D.B. Calne  and
K. Waterman
T.A. Hurwitz*
Affiliation:
Department of Psychiatry and Division of Neurology, University of British Columbia, Vancouver
D.B. Calne
Affiliation:
Department of Psychiatry and Division of Neurology, University of British Columbia, Vancouver
K. Waterman
Affiliation:
Department of Psychiatry and Division of Neurology, University of British Columbia, Vancouver
*
Department of Psychiatry, UBC Health Sciences Center Hospital, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2A8
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Two Parkinsonian patients with chronic nonconfusional dopaminomimetic psychosis were treated with a course of electroconvulsive therapy. In both cases sustained remission of psychosis was obtained in the face of ongoing administration of dopaminomimetics.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 15 , Issue 1 , February 1988 , pp. 32 - 34
Copyright
Copyright © Canadian Neurological Sciences Federation 1988

References

REFERENCES

1.Goodwin, FK. Behavioural effects of 1-dopa in man. Semin Psychiatry 1971; 3: 477–492.Google Scholar
2.Damasio, AR, Lobo-Antunes, J, Macedo, C. Psychiatric aspects in parkinsonism treated with 1-dopa. J Neurol Neurosurg Psychiatry 1971; 34: 502–507.CrossRefGoogle Scholar
3.Celesta, GC, Barr, AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970; 23: 193–200.CrossRefGoogle Scholar
4.Parkes, JD. Adverse effects of antiparkinsonian drugs. Drugs 1981; 21: 341–353.CrossRefGoogle ScholarPubMed
5.Klawans, HL. What to do when sinemet fails: Part one. Clin Neuropharmacol 1984; 7: 121–133.Google Scholar
6.Marsden, CD, Fahn, S. Problems in Parkinson’s disease. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London: Butterworth Scientific 1982; 1–7.Google Scholar
7.Lebensohn, ZM, Jenkins, RB, Improvement of parkinsonism in depressed patients treated with ECT. Am J Psychiatry 1975; 132: 283–285.Google ScholarPubMed
8.Asnis, G. Parkinson’s disease, depression and ECT: A review and case study. Am J Psychiatry 1977; 134: 191–195.Google ScholarPubMed
9.Levy, L, Savit, JM, Hodes, M. Parkinsonism: Improvement by electroconvulsive therapy. Arch Phys Med Rehabil 1983; 64: 432–433.Google ScholarPubMed
10.Lipper, S, Bermanzohn, PC. Electroconvulsive therapy in patients with parkinsonism. Am J Psychiatry 1975; 132:457.Google ScholarPubMed
11.Duvoisin, RC, The evaluation of extrapyramidal disease. In: de Ajuriaguerra, J, Gauthier, G, eds. Monoamines noyaux gris centraux et syndrome de Parkinson. Paris: Masson and Cie 1971; 313–325.Google Scholar
12.Overall, JE, Gorham, DR. The brief psychiatrie rating scale. Psychological Reports 1962; 10: 799–812.CrossRefGoogle Scholar
13.Folstein, MF, Folstein, SE, McHugh, PR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.CrossRefGoogle ScholarPubMed
14.Hoehn, MM, Yahr, MD. Parkinsonism; onset, progression and mortality. Neurology 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
15.Nausieda, PA, Weiner, WJ, Kaplan, LR, et al., Sleep disruption in the course of chronic levodopa therapy: An early feature of the levodopa psychosis. Clinical Neuropharmacol 1982; 5: 183–194.CrossRefGoogle ScholarPubMed
16.Sacks, OW, Kohl, MS, Messeloff, CR, et al. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972; 22:516–519.CrossRefGoogle ScholarPubMed
17.Birkmayer, W, Danielczyk, W, Neumayer, E, et al. Nucleus ruber and 1-dopa psychosis: biochemical post-mortem findings. J Neural Transm 1974;35:93–116.CrossRefGoogle Scholar
18.Birkmayer, W, Danielczyk, W, Neumayer, E, et al. Dopaminergic supersensitivity in parkinsonism. In: Calne, DB, Chase, TN, Barbeau, A, eds. Advances in Neurology. New York: Vol 9, Raven Press 1975; 121–129.Google ScholarPubMed
19.Nausieda, PA, Tanner, CM, Klawans, HL. Serotonergically active agents in levodopa induced psychiatric toxicity. In: Fahn, S, Calne, DB, Shoulson, I, eds. Advances in Neurology. New York: Vol 37, Experimental Therapeutics of Movement Disorders, Raven Press 1983; 23–31.Google ScholarPubMed
20.Beasley, BL, Nutt, JG, Davenport, RW, et al. Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 1980;37:155–156.CrossRefGoogle ScholarPubMed
21.Moksovitz, C, Moses, H, Klawans, HL. Levodopa-induced psychosis:A kindling phenomenon. Am J Psychiatry 1978; 135: 669–675.Google Scholar
22.Klawans, HL, Crossett, P, Dana, N. Effect of chronic amphetamine exposure on stereotyped behaviour: Implications for pathogenesis of 1-dopa-induced dyskinesias. In: Calne, DB, Chase, TN, Barbeau, A, eds. Advances in Neurology. New York: Raven Press 1975; 105–112.Google ScholarPubMed
23.Klawans, HL, Margolin, D. Amphetamine-induced dopaminergic hypersensitivity in guinea pigs, implications in psychosis and human movement disorders. Arch Gen Psychiatry 1975; 32: 725–732.CrossRefGoogle ScholarPubMed
24.Klawans, HL, Goetz, C, Nausieda, PA, et al. Levodopa induced dopamine receptor hypersensitivity. Ann Neurol 1977;2:125–129.CrossRefGoogle Scholar
25.Nausieda, PA, Weiner, WJ, Kanapa, DJ. Bromocriptine-induced behavioural hypersensitivity: Implications for the therapy of parkinsonism. Neurology 1978; 28: 1183–1188.CrossRefGoogle ScholarPubMed
26.Scholz, E, Dichgans, J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatra Neurol Sci 1985; 235: 60–64.CrossRefGoogle ScholarPubMed
27.Bischoff, S. The hippocampus as a site of action for antipsychotic activity of neuroleptics. Experimentia 1985; 41: 1217.Google Scholar
28.Idànpàân-Heikkila, J, Alhava, E, Olkinuora, M, et al. Agranulocytosis during treatment with clozapine. Europ J Clin Pharmacol 1977; 11:193–198.CrossRefGoogle Scholar
29.Modigh, K, Balldin, J, Eriksson, E, et al. Increased responsiveness of dopamine receptors after ECT & A review of experimental and clinical evidence. In: Lerer, B, Weiner, RD, Belmaker, H, eds. ECT: Basic Mechanisms. London: John Libbey & Co 1984; 18–27.Google Scholar
30.Balldin, J, Edén, S, Granérus, A-K, et al. Electroconvulsive therapy in Parkinson’s syndrome with “on-off” phenomena. J Neural Transm 1980; 47: 11–21.CrossRefGoogle Scholar
31.Balldin, J, Granérus, A-K, Lindstedt, G, et al. Predictors for improve-ment after electroconvulsive therapy in parkinsonian patients with on-off symptoms. J Neural Transm 1981; 52: 199–211.CrossRefGoogle Scholar
32.Ward, C, Stern, GM, Pratt, RTC, et al. Electroconvulsive Therapy in parkinsonian patients with the “on-off” syndrome. J Neural Transm 1980; 49: 133–135.CrossRefGoogle ScholarPubMed
33.Lerer, B., Jabotinsky-Rubin, K, Bannet, J, et al. Electroconvulsive shock prevents dopamine receptor supersensitivity. Eur J Pharmacol 1982; 80: 131–134.CrossRefGoogle ScholarPubMed